Migraine, a Challenge for the General Practitioner
Journal: Advances in Medicine and Engineering Interdisciplinary Research DOI: 10.32629/ameir.v2i3.2602
Abstract
Headache is always a challenge for the physician because it is one of the most frequent reasons for consultation in outpatient pathology. We know that the first challenge is to make the differential diagnosis between the primary headaches (like migraine and tensional type headache), and secondary headaches. However, primary headaches account for almost 90% of consultations, and within these, migraine has currently become one of the greatest challenges for medicine, due to the great deterioration in the patient's quality of life and the associated family, social and labor costs.
Keywords
migraine; headache; analgesics; chronic migraine; preventive
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1]Lavados PM, Gomez V, Sawada M, Chomali M, Alvarez M. 2003. Diagnósticosneurológicos en la atención primaria de salud en Santiago, Chile. Rev Neurol, 36(6): 518-522.
[2]Headache Classification Committee of the International Headache Society (IHS). 2018. The International Classification of Headache Disorders, 3er edition. Cephalalgia, 38(1): 1-211.
[3]Randall C, Clunch D. 2001. Evaluation of acute headache in adults. Am Fam Physician, 15(63): 685-693.
[4]Chou D. 2018. Secondary headaches syndromes. Headache, 24(4): 1179-1191.
[5]Stovner L, et al. 2018. Global, regional and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 17: 954-976.
[6]Steiner TJ. 2004. Lifting the burden: the global campaine to reduce the burden of headache worldwide. Lancet Neurology, 3(4):204-205.
[7]World Health Organization (2001). The World Health Report 2001-WHO. Geneva.
[8]Goadsby P. 2009. Pathophysiology of migraine. Neurol Clin, 27: 335-368.
[9]Dodick D. 2018. A phase-by-phase review of migraine pathophysiology. Headache, 58. (Supp1): 4-16.
[10]Durham P. 2006. Calcitonin Gene - Related Peptide (CGRP) and Migraine. Headache, 46(Suppl1): S3-S8.
[11]Evans R, Rozen T, Mechtler L. 2008. Neuroimaging and other diagnostic testing in headache. Silberstein S, Lipton R, Dodick D. Wolff's Headache (8ºEd), pp. 63-93.
[12]Detsky M, McDonald D, Baerlocher M, Tomlinson G, McCrory D, Booth C. 2006. Does the patient with headache have a migraine need neuroimaging. JAMA, 296: 1274-1283.
[13]Loder E, Weisenbaum E, Frishberg B, et al. 2013. Choosing Wisely in Headache Medicine: The American Headache Society's list of five things physicians and patient should questions. Headache, 53: 1651-1659.
[14]Buse DC, et al. 2013. Psychiatric comorbidities of episodic and chronic migraine. J Neurik, 260(8): 1960-1969.
[15]Sevillano-García MD, Manso-Calderón R, Cacabelos-Perez P. 2007. Comorbilidades en la migraña: derpesión, ansiedad, estrés ytrastornos del sueño. Rev Neurol, 45: 400-405.
[16]Magalhaes JE, Sampaio PA. 2018. Migraine and cerebrovascular diseases:epidemiology, pathophysiological, and clinical considerations. Headache, 1277-1286.
[17]Sun Eldestein C, Manskop A. 2011. Alternatives headaches treatment. Nutraceuticals, behavioral and physical treatments. Headache, 51(3): 469-483.
[18]Da Silva AN. 2015. Acupuncture for migraine prevention. Headache, 55(3): 470-473
[19]Vargas B. 2018. Acute treatment of migraine. Headache, pp. 1032-1052.
[20]Evers S, Afra J, Frese A, et al. 2009. EFNS guidelines on the drug treatment of migraine- revised report of an EFNS task force. Eur J Neurol, 16: 968-981.
[21]Marmura MJ, Silverstein S. 2015. The acute treatment of migraine in adults: The American Headache Society evidence assessment of migraine pharmacotherapies. Headache, 55: 3-20.
[22]Kelley N, Tepper D. 2012. Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post discharge medication. Headache, 52: 467-482.
[23]Bigal M, Lipton R. 2009. Excessive opioids use and the development of chronic migraine. Pain, 142: 179-182.
[24]Tepper SJ. 2012. Opioids should not be used in migraine. Headache, 52: S30-34.
[25]Levin M. 2014. Opioids in migraine. Headache, 54: 12-21.
[26]Kelley N, Tepper D. 2012. Rescue therapy for acute migraine. Part 1: Triptan, Dihydroergotamine and magnesium. Headache, 52(1): 114-128.
[27]Lainez JM, et al. 2013. Optimal management of severa nausea and vomiting in migraine: improving patient outcome. Patient Relat Outcome Meas, 4: 61-73.
[28]Lipton RB, et al. 2007. AMPP Advisory Group: migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68(5):343-349.
[29]Schwedt T. 2018. Preventive therapy of migraine. Headache, 24(4): 1052-1065.
[30]Silverstein SD, et al. 2012. Evidence-based guideline update: pharmacologic treatments for episodic migraine prevention in adults. Neurology, 78: 1337-1345.
[31]Loder E, Burch R, Rizzoli P. 2012. The 2012 AHS/AAN Guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache, 52: 930-945.
[32]Jacson J, Shimeall W, Sessums L, et al. 2010. Tricyclic antidepressant and headaches: systematic review and meta-analysis. BMJ, 341: c5250.
[33]Linde M, Mullness W, Chronicle E, McCrory D. 2013. Topiramate for theprophylaxis of episodic migraine in adults. Cochrane Database Syst Rev, 6: CD010610
[34]Diener HC, et al. 2007. Topiramate reduces headaches days in chronic migraine: a randomized double-blind placebo controlled study. Cephalalgia, 27: 814-823.
[35]Linde M, Mullness W, Chronicle E, McCrory D. 2013. Gabapentin or pregabaline for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev, 6: CD010609.
[36]Bigal M, Serrano D, Reed M, Lipton R. 2008. Chronic migraine in the population. Neurology, 71: 559-566.
[37]Lipton RB, Silverstein SD. 2015. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache, 55(2): 103-122.
[38]May A. 2016. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol, 12(8):455-464.
[39]Cho SJ, Song TJ, Chu MK. 2017. Treatment update of chronic migraine. Curr Pain Headache Rep, 21: 26.
[40]Pascual J. 2012. Migraña crónica: tratamiento. Rev Neurol, 54(Suppl2): S31-S38.
[41]Silverstein SD, Lipton RB, Dodick DW. 2007. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized double-blind placebo-controlled trail. Headache, 47: 170-180.
[42]Diener H, Dodick D, Aurora S, et al. 2010. PREEMPT 2 Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: results for the double blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia, 32(5): 804-814.
[43]Couch JR. 2011. Amitriptyline versus placebo study group: amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache, 51(1): 33-51.
[44]Yurekli VA, et al. 2008. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain, 9(1): 37-41.
[45]Spira PJ, Beran R. 2003. Australian gabapentin chronic daily headache group. Gabapentin in the prophylaxis of chronic daily headache: a randomized placebo controlled study. Neurology, 61(12): 1753-1759
[46]Sacco S, Bendtsen L, Ashina M, et al. 2019. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain, 20(1): 6.
[47]Diener HC, et al. 2016. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol, 12(10): 575-583.
[48]Carlsen L, Murkjaard S, et al. 2018. Complete detoxification is the most effective treatment of medication-overuse headache. A randomized controlled open-label trial. Cephalalgia, 38(2): 225-236.
[49]Lipton R, Silberstein S, Saper J, Bigal M, Goadsby P. 2003. Why headache treatment fails? Neurology, 60: 1064-1070.
[2]Headache Classification Committee of the International Headache Society (IHS). 2018. The International Classification of Headache Disorders, 3er edition. Cephalalgia, 38(1): 1-211.
[3]Randall C, Clunch D. 2001. Evaluation of acute headache in adults. Am Fam Physician, 15(63): 685-693.
[4]Chou D. 2018. Secondary headaches syndromes. Headache, 24(4): 1179-1191.
[5]Stovner L, et al. 2018. Global, regional and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 17: 954-976.
[6]Steiner TJ. 2004. Lifting the burden: the global campaine to reduce the burden of headache worldwide. Lancet Neurology, 3(4):204-205.
[7]World Health Organization (2001). The World Health Report 2001-WHO. Geneva.
[8]Goadsby P. 2009. Pathophysiology of migraine. Neurol Clin, 27: 335-368.
[9]Dodick D. 2018. A phase-by-phase review of migraine pathophysiology. Headache, 58. (Supp1): 4-16.
[10]Durham P. 2006. Calcitonin Gene - Related Peptide (CGRP) and Migraine. Headache, 46(Suppl1): S3-S8.
[11]Evans R, Rozen T, Mechtler L. 2008. Neuroimaging and other diagnostic testing in headache. Silberstein S, Lipton R, Dodick D. Wolff's Headache (8ºEd), pp. 63-93.
[12]Detsky M, McDonald D, Baerlocher M, Tomlinson G, McCrory D, Booth C. 2006. Does the patient with headache have a migraine need neuroimaging. JAMA, 296: 1274-1283.
[13]Loder E, Weisenbaum E, Frishberg B, et al. 2013. Choosing Wisely in Headache Medicine: The American Headache Society's list of five things physicians and patient should questions. Headache, 53: 1651-1659.
[14]Buse DC, et al. 2013. Psychiatric comorbidities of episodic and chronic migraine. J Neurik, 260(8): 1960-1969.
[15]Sevillano-García MD, Manso-Calderón R, Cacabelos-Perez P. 2007. Comorbilidades en la migraña: derpesión, ansiedad, estrés ytrastornos del sueño. Rev Neurol, 45: 400-405.
[16]Magalhaes JE, Sampaio PA. 2018. Migraine and cerebrovascular diseases:epidemiology, pathophysiological, and clinical considerations. Headache, 1277-1286.
[17]Sun Eldestein C, Manskop A. 2011. Alternatives headaches treatment. Nutraceuticals, behavioral and physical treatments. Headache, 51(3): 469-483.
[18]Da Silva AN. 2015. Acupuncture for migraine prevention. Headache, 55(3): 470-473
[19]Vargas B. 2018. Acute treatment of migraine. Headache, pp. 1032-1052.
[20]Evers S, Afra J, Frese A, et al. 2009. EFNS guidelines on the drug treatment of migraine- revised report of an EFNS task force. Eur J Neurol, 16: 968-981.
[21]Marmura MJ, Silverstein S. 2015. The acute treatment of migraine in adults: The American Headache Society evidence assessment of migraine pharmacotherapies. Headache, 55: 3-20.
[22]Kelley N, Tepper D. 2012. Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post discharge medication. Headache, 52: 467-482.
[23]Bigal M, Lipton R. 2009. Excessive opioids use and the development of chronic migraine. Pain, 142: 179-182.
[24]Tepper SJ. 2012. Opioids should not be used in migraine. Headache, 52: S30-34.
[25]Levin M. 2014. Opioids in migraine. Headache, 54: 12-21.
[26]Kelley N, Tepper D. 2012. Rescue therapy for acute migraine. Part 1: Triptan, Dihydroergotamine and magnesium. Headache, 52(1): 114-128.
[27]Lainez JM, et al. 2013. Optimal management of severa nausea and vomiting in migraine: improving patient outcome. Patient Relat Outcome Meas, 4: 61-73.
[28]Lipton RB, et al. 2007. AMPP Advisory Group: migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68(5):343-349.
[29]Schwedt T. 2018. Preventive therapy of migraine. Headache, 24(4): 1052-1065.
[30]Silverstein SD, et al. 2012. Evidence-based guideline update: pharmacologic treatments for episodic migraine prevention in adults. Neurology, 78: 1337-1345.
[31]Loder E, Burch R, Rizzoli P. 2012. The 2012 AHS/AAN Guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache, 52: 930-945.
[32]Jacson J, Shimeall W, Sessums L, et al. 2010. Tricyclic antidepressant and headaches: systematic review and meta-analysis. BMJ, 341: c5250.
[33]Linde M, Mullness W, Chronicle E, McCrory D. 2013. Topiramate for theprophylaxis of episodic migraine in adults. Cochrane Database Syst Rev, 6: CD010610
[34]Diener HC, et al. 2007. Topiramate reduces headaches days in chronic migraine: a randomized double-blind placebo controlled study. Cephalalgia, 27: 814-823.
[35]Linde M, Mullness W, Chronicle E, McCrory D. 2013. Gabapentin or pregabaline for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev, 6: CD010609.
[36]Bigal M, Serrano D, Reed M, Lipton R. 2008. Chronic migraine in the population. Neurology, 71: 559-566.
[37]Lipton RB, Silverstein SD. 2015. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache, 55(2): 103-122.
[38]May A. 2016. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol, 12(8):455-464.
[39]Cho SJ, Song TJ, Chu MK. 2017. Treatment update of chronic migraine. Curr Pain Headache Rep, 21: 26.
[40]Pascual J. 2012. Migraña crónica: tratamiento. Rev Neurol, 54(Suppl2): S31-S38.
[41]Silverstein SD, Lipton RB, Dodick DW. 2007. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized double-blind placebo-controlled trail. Headache, 47: 170-180.
[42]Diener H, Dodick D, Aurora S, et al. 2010. PREEMPT 2 Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: results for the double blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia, 32(5): 804-814.
[43]Couch JR. 2011. Amitriptyline versus placebo study group: amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache, 51(1): 33-51.
[44]Yurekli VA, et al. 2008. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain, 9(1): 37-41.
[45]Spira PJ, Beran R. 2003. Australian gabapentin chronic daily headache group. Gabapentin in the prophylaxis of chronic daily headache: a randomized placebo controlled study. Neurology, 61(12): 1753-1759
[46]Sacco S, Bendtsen L, Ashina M, et al. 2019. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain, 20(1): 6.
[47]Diener HC, et al. 2016. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol, 12(10): 575-583.
[48]Carlsen L, Murkjaard S, et al. 2018. Complete detoxification is the most effective treatment of medication-overuse headache. A randomized controlled open-label trial. Cephalalgia, 38(2): 225-236.
[49]Lipton R, Silberstein S, Saper J, Bigal M, Goadsby P. 2003. Why headache treatment fails? Neurology, 60: 1064-1070.
Copyright © 2024 María Loreto Cid
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License